

Resource Summary Report

Generated by RRID on Aug 4, 2026

Memorial Sloan Kettering Cancer Center Antibody and Bioresource Core Facility

RRID:SCR_017691

Type: Tool

Proper Citation

Memorial Sloan Kettering Cancer Center Antibody and Bioresource Core Facility
(RRID:SCR_017691)

Resource Information

URL: <https://www.mskcc.org/research/ski/core-facilities/monoclonal-antibody-core-facility>

Proper Citation: Memorial Sloan Kettering Cancer Center Antibody and Bioresource Core Facility (RRID:SCR_017691)

Description: ABCF can provide MABs from established hybridomas for RESEARCH PURPOSES ONLY, can assist in generating MABs, offers a weekly mycoplasma contamination screening service for tissue culture samples, distributes cell lines developed at Memorial Sloan Kettering Cancer Center and Rockefeller University.

Abbreviations: ABCF

Synonyms: Antibody and Bioresource Core Facility

Resource Type: access service resource, core facility, service resource

Keywords: Monoclonal, antibody, hybridoma, mycoplasma, screening, service, tissue, culture, sample, cell, line, core

Funding: NCI P30 CA008748

Availability: Restricted

Resource Name: Memorial Sloan Kettering Cancer Center Antibody and Bioresource Core Facility

Resource ID: SCR_017691

Alternate IDs: SCR_017709, ABRF_51

Alternate URLs: https://ilab.mskcc.org/service_center/show_external/3451,
<https://coremarketplace.org/?FacilityID=85>

Record Creation Time: 20220129T080336+0000

Record Last Update: 20260805T044416+0000

Ratings and Alerts

No rating or validation information has been found for Memorial Sloan Kettering Cancer Center Antibody and Bioresource Core Facility.

No alerts have been found for Memorial Sloan Kettering Cancer Center Antibody and Bioresource Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bindeman WE, et al. (2025) Loss of IL13RA2 promotes metastatic tumor growth in triple-negative breast cancer via increased AKT and NF- κ B signaling. Clinical & experimental metastasis, 42(5), 40.